Moderna/$MRNA
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Moderna
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 25 mRNA development candidates in clinical studies as of March 2026. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
- Ticker
- $MRNA
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 4,700
- Headquarters
- Cambridge, United States
- Website
- www.modernatx.com
Moderna Metrics
BasicAdvanced
$80B
-
-$8.01
1.11
-
Price and volume
Market cap
$80B
Beta
1.11
52-week high
$254.48
52-week low
$22.28
Average daily volume
19M
Financial strength
Current ratio
2.295
Quick ratio
2.034
Long term debt to equity
0.183
Total debt to equity
0.183
Interest coverage (TTM)
-55.36%
Profitability
EBITDA (TTM)
-2,195
Gross margin (TTM)
-66.02%
Net profit margin (TTM)
-141.43%
Operating margin (TTM)
-109.34%
Effective tax rate (TTM)
-2.07%
Revenue per employee (TTM)
$470,000
Management effectiveness
Return on assets (TTM)
-13.26%
Return on equity (TTM)
-39.00%
Valuation
Price to revenue (TTM)
35.341
Price to book
11.81
Price to tangible book (TTM)
11.81
Price to free cash flow (TTM)
-63.295
Free cash flow yield (TTM)
-1.58%
Free cash flow per share (TTM)
-3.161
Growth
Revenue change (TTM)
-27.62%
Earnings per share change (TTM)
6.47%
3-year revenue growth (CAGR)
-40.64%
3-year earnings per share growth (CAGR)
37.86%
What the Analysts think about Moderna
Analyst ratings (Buy, Hold, Sell) for Moderna stock.
Analyst projections of the future price of Moderna stock.
Bulls say / Bears say
Moderna and Merck reported that their Phase 3 melanoma cancer-vaccine trial met its recurrence-free and distant-metastasis-free survival endpoints against Keytruda alone. This is an important clinical proof point for Moderna’s oncology programme, though overall-survival results are still pending. (Reuters)
The FDA approved mFlusiva, the first mRNA seasonal flu vaccine in the US, for adults aged 50 and older. A late-stage trial found it was 26.6% more effective than a standard-dose flu vaccine, giving Moderna a new product beyond COVID vaccines. (Reuters)
Moderna remained deeply loss-making: it posted a $782 million net loss in the second quarter and cash and investments fell to $6.9 billion from $7.5 billion in the prior quarter. It expects only $4.7 billion to $5.2 billion at year-end, leaving limited room for prolonged delays in turning its pipeline into sales. (SEC)
COVID vaccine sales remain under pressure: Moderna said lower US and South American sales were offset by international deliveries and partnership revenue in the second quarter. That leaves near-term performance reliant on seasonal demand and government contracts as the company seeks to replace its pandemic-era business. (Reuters, SEC)
Moderna’s Phase 3 norovirus vaccine trial did not meet the statistical criteria for early success at its interim analysis, and the company plans to enrol an additional cohort. This delays clarity on a potential pipeline product and leaves its eventual benefit uncertain. (SEC)
Data summarised monthly by Lightyear AI. Last updated on 22 Oct 2026.
Moderna Financial Performance
Revenues and expenses
Moderna Earnings Performance
Company profitability
Upcoming events
No upcoming events
Moderna News
AllArticlesVideos
Funds containing Moderna
AllUSDEURGBP
Fund name | Fund size | $MRNA weighting |
|---|---|---|
iShares Nasdaq US Biotechnology$BTEC | $1.1B | 5.32% |
iShares Nasdaq US Biotechnology£BTEK | $1.1B | 5.32% |
iShares Healthcare Innovation€2B78 | $1.2B | 5.00% |
iShares Healthcare Innovation$HEAL | $1.3B | 5.00% |
iShares Healthcare Innovation£DRDR | $1.3B | 5.00% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.